The FDA signaled a clearer path for cannabis-derived drug applications, emphasizing safety data and consistent manufacturing controls.
Officials highlighted the need for standardized dosing and long-term monitoring for new cannabinoid therapies.
Industry teams said the guidance may shorten review timelines but will require more rigorous clinical data.
The agency is expected to publish additional technical guidance later this year.